 I. To determine the maximum tolerated dose MTD of the combination of sunitinib sunitinib malate Sutent, an oral tyrosine kinase inhibitor with antiangiogenic activity that inhibits vascular endothelial growth factor receptor 2 VEGFR2, stem cell factor receptor c-kit and platelet derived growth factor receptor PDGFR, in combination with hydroxychloroquine HCQ, an inhibitor of autophagy, in patients with advanced solid tumors that are refractory to standard chemotherapy. 